The Top Three Nuclear Energy Stocks to Buy Right Now

15%: Cameco supplied 15% of global uranium in 2025 and posted revenue +11% and EPS +114% year-over-year, with a 16.93% net margin and a 0.14 debt/equity ratio. Constellation operates 21 of the U.S.'s 94 reactors, delivered revenue +8.34% in 2025, a 9.1% net margin, 0.61 D/E and a 0.57% dividend yield (21% payout), while BWX saw revenue +18% and EPS +20% and is advancing factory-built small modular reactors leveraging ~400 naval reactors of experience.

Analysis

The near-term winners are capital-light, high-margin exposures that benefit from an accelerating need for firm, high-density baseload — that favors vertically integrated producers and specialists that control key steps of the fuel cycle. A sustained rerating requires a multi-year tightening of secondary supply and conversion/enrichment capacity; absent that, spot bursts will produce mean-reverting equity moves and dispersion across producers.

Small modular reactors (SMRs) create a bifurcated opportunity set: industrial OEMs with repeatable factory production and defense-funded IP can monetize early contracts and derisk commercialization, while conventional utilities capture demand via long-term offtakes and corporate PPAs. The critical second-order bottlenecks are not fuel per se but heavy forgings, specialty alloys, and scalable factory assembly — companies sitting on those inputs will see margin expansion ahead of obvious reactor milestones.

Principal tail risks are regulatory timing and financing: NRC/peer-country approvals are binary and mismatches between project finance and capital market windows can push commercialization timelines from years into decades. Geopolitical shifts that restore large low-cost secondary uranium flows or rapid success of alternative firming (e.g., long-duration storage + renewable buildouts) would collapse the premium assigned to miners and SMR contractors.

Consensus currently underweights the optionality embedded in defense-derived industrial capacity converting to civilian SMR scale; that optionality is asymmetric because early fixed-price factory contracts scale profitably but are lost if competitors secure forgings and site-permits first. Position sizing should therefore reflect binary licensing and multi-year rollout risk rather than near-term revenue prints.

Key Decisions for Investors

• Long CCJ (12–36 months): establish a 3–5% portfolio position in CCJ equity to capture a supply-tightness re-rating; set tactical stop-loss at -20% and target asymmetric upside of +80–150% if uranium/conversion tightness persists. Rationale: price-to-resource optionality and low-cost tiers should re-lever to rising spot and contract cycles.
• Long BWXT via LEAPS (18–48 months): buy Jan‑2028 LEAPS (ATM or modestly OTM) sized 1–2% of portfolio and finance by selling 6–12 month OTM calls to trim premium. Rationale: buy optionality on SMR commercialization and defense-to-civil conversion while monetizing time decay; exit or trim on failed licensing or missed factory milestones.
• Overweight CEG (12–24 months) with income overlay: take a 2–4% position in CEG equity for durable cash flows and sell one-year covered calls to boost yield; stop-loss at -15%. Rationale: capture contracted baseload demand from corporate PPAs and limited downside relative to merchant generation names.
• Event-driven options on BWXT around regulatory windows (6–18 months): purchase short-dated calls ahead of announced NRC/agency license decision dates sized as a small asymmetric bet (0.5–1% of portfolio). Rationale: sharp upside on positive licensing; cap loss to premium paid.